Other potential targets for CCL5 release reduction include demyelinating and infectious diseases, as studies assessing the CSF from people with MS have revealed increased CCL5 levels among patients with an active form of disease [121,131,132,133]. Here, CCL5 is linked to myeloid sarcoma.